-+ 0.00%
-+ 0.00%
-+ 0.00%

TScan reports Phase 1 Cohort C data showing 11 of 14 patients reach complete donor chimerism after TSC-101 infusion

PUBT·06/22/2026 11:01:14
Listen to the news
TScan reports Phase 1 Cohort C data showing 11 of 14 patients reach complete donor chimerism after TSC-101 infusion
  • TScan Therapeutics presented initial Phase 1 Cohort C data from the ALLOHA study of TSC-101 in patients undergoing allogeneic stem cell transplant.
  • Most treated patients reached full donor cell replacement quickly, with the remaining patients trending toward the same outcome.
  • Safety remained favorable, with side effects broadly consistent with typical post-transplant complications.
  • The company expects to enroll its first patient in the pivotal Phase 3 ALLOHA-2 study this month.
  • A virtual KOL event is scheduled for today to review the Cohort C readout and Phase 3 plans.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TScan Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606220700PRIMZONEFULLFEED9750090) on June 22, 2026, and is solely responsible for the information contained therein.